COMBINED THERAPY OF POST-STROKE DEPRESSIONS: VENFLAXIN AND COGNITIVE-BEHAVIORIAL PSYCHOTHERAPY
https://doi.org/10.21518/2079-701X-2017-11-194-197
Abstract
An experience of combined therapy (by Venflaxin and cognitive-behavioral psychotherapy) of post-stroke depressions of the rehabilitation inpatient department patients. 38 patients with organic depressive disturbance of various severity degree by ICD-10 were examined. By the domineering effect the patients were divided in 4 groups – with predominance of the anxiety component, melancholy-anxiety combined variant, “classical” melancholic depression and astheno-depressive syndrome with the unstable main effect. With use of the psychometric scales HADS, HARS, CGI-S и CGI-I effectiveness of the combined therapy was demonstrated with respect to all components of the post-stroke depression, advanced reduction of the anxiety component was observed. Good tolerability and safety of Venlafaxin was noted. A conclusion about the rationality to use Venflaxin in a combination with a cognitive-behavioral psychotherapy and rehabilitation of neurologic patients in the post-stroke period.
About the Authors
I. N. Agamamedova
Moscow Psychiatry Scientific and Research Institute – an affiliate of the Serbsky Federal Medical Research Center of Psychiatry and Narcology
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
Т. Е. Nikitina
Moscow Psychiatry Scientific and Research Institute – an affiliate of the Serbsky Federal Medical Research Center of Psychiatry and Narcology
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Аведисова А.С. Венлафаксин (Велаксин): результаты международных исследований антидепрессанта III поколения. Психиатрия и психофармакотерапия, 2006, 11(2).
2. Агамамедова И.Н., Никитина Т.Е., Бобров А.Е. Опыт работы психотерапевтического кабинета многопрофильной клиники медицинской реабилитации. Социальная и клиническая психиатрия, 2016, 26(3): 46-52.
3. Вознесенская Т.Г. Депрессия при цереброваскулярных заболеваниях. Неврология нейропсихиатрия и психосоматика, 2009, 2: 9-13.
4. Краснов В.Н., Крюков В.В. Велаксин (венлафаксин) в современной терапии депрессий: результаты первого российского многоцентрового исследования эффективности и безопасности. Психиатрия и психофармакотерапия, 2007, 4: 29-32.
5. Хабарова Т.Ю. Особенности психотерапевтической коррекции тревожно-депрессивных расстройств у пациентов с церебральным инсультом в раннем восстановительном периоде. Молодой ученый, 2015, 14: 108-112.
6. Berg A, Psych L, Lonnqvist J et al. Assessment of Depression After Stroke. A Comparison of Different Screening Instruments. Stroke, 2009, 40: 523-9.
7. Capaldi V, Wynn I. Emerging strategies in the treatment of post-stroke depression and psychiatric distress in patients. Psychol Res Behav Manag, 2010, 3: 109-18.
8. Casciano R. Effectiveness measures of major depressive disorder in pharmacoeconomic evaluations. Manag. Care Interface, 2003, Suppl B: 14-15.
9. Ciusani E, Zullino DF. Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J. Psychopharmacol., 2004, 18: 559-566
10. Gaete JM, Bogousslavsky J. Post-stroke depression. Exp Rev Neurother, 2008, 8: 75–92.
11. Williams LS, Shoma Ghose S, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry, 2004, 161: 1090-5.
12. Gaete JM, Bogousslavsky J. Post-stroke depression. Exp Rev Neurother, 2008, 8: 75-92.
13. Hacket ML, Anderson CS. Treatments options for post-stroke depression in the elderly. Aging Health, 2005, 1: 90-5.
14. Hackett ML, Anderson CS, House AO et al. Interventions for Treating Depression After Stroke. Stroke, 2009, 40: e487-8.
15. Hackett ML, Yapa C, Parag V et al. Frequency depression after stroke: a systematical review of observational studies. Stroke, 2005, 36: 1330-40.
16. Kanner AM. Depression in neurological disorders. Lundbec Inst, 2005, 161 p.
17. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. (1997): Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol. Bull., 33: 149-154.
18. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology, 2004, 50: 57-64.
19. Robinson RG, Jorge RE, Moser DJ. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA, 2008, 299: 2391-400.
20. Sir A, D’Souza RF, Uguz S, George T, Vahip S. Hopwood M, Martin AJ, Lam W, Burt T. Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. J. Clin. Psychiatry, 2005, 66: 1312-1320.
21. Stahl SM, Grady MM, Moret C, Briley M. SNRIs their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectr, 2005, 10: 732-747.
22. Van Amerongen AP, Ferrey G, Toumoux A. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J. Affect Disord., 2002, 7Z: 21-31.
23. Van Baardewijk M, Vis PM, Einarson TR. Cost effectiveness of duloxe-tine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr. Med. Res. Opin., 2005, 21: 1271-1279.
24. Zerjav S, Tse G. Review of duloxetine and venlafaxine in depression Canad. Pharmacists J, 2009, 142(3): 144-152.
Review
For citations:
Agamamedova IN, Nikitina ТЕ. COMBINED THERAPY OF POST-STROKE DEPRESSIONS: VENFLAXIN AND COGNITIVE-BEHAVIORIAL PSYCHOTHERAPY. Meditsinskiy sovet = Medical Council. 2017;(11):194-197. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-194-197
Views:
845
Email this article 